Vaccinex, Inc.
1895 Mt. Hope Avenue
Rochester
New York
14620
United States
Tel: 585-271-2700
Fax: 585-271-2766
Website: http://www.vaccinex.com/
Email: info@vaccinex.com
117 articles about Vaccinex, Inc.
-
Vaccinex to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event
1/5/2021
Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that it will participate in the 10th Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021. Maurice Zauderer, Ph.D., President and CEO, will host 1x1 meetings and will present a corporate update on Wednesday, January
-
Vaccinex Reports Third Quarter 2020 Financial Results and Provides Corporate Update
11/13/2020
Addition al data from SIGNAL Huntington’s disease (HD) trial support continued development in H D and in Alzheimer’s disease (AD) Phase 1/2 Study to Evaluate Pepinemab in Combination with KEYTRUDA ® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for H1 2021 Ended the quarter with cash and cash equivalents of $17.1 million
-
Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference
10/29/2020
SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington’s disease Data provide strong rationale for continued development in Huntington’s and other slowly progressive neurodegenerative diseases, including Alzheimer’s
-
CORRECTION -- Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference
10/29/2020
SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington’s disease
-
Vaccinex, Inc. to Present at the Virtual Investor KOL RoundtableLive moderated video webcast discussion between members of management and Key Opinion Leader, Eric Siemers, MD on Tuesday, October 27th at 10:00 a.m. EDT
10/26/2020
Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, announced today that members of management will participate in the Virtual Investor KOL Roundtable on Tuesday, October 27, 2020 at 10:00 AM ET. Participating in the KOL Roundtable discussion will be Maurice Zauderer, Ph.D., President and Chief Executive
-
Clinical Catch-Up: September 21-25
9/28/2020
The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look. -
Top-Line Results of Phase 2 SIGNAL Study in Huntington’s Disease Support Potential for Cognitive Benefit of Pepinemab
9/22/2020
K ey cognitive endpoint s trending towards but did not reach statistical significance in early manifest population . O verall study does not meet pre-specified co- primary endpoints Results support continued development in Alzheimer’s disease and in mid-stage Huntington’s disease patients with greater cognitive deficits Company to host investor conference call today, September 22, at 8:30 a.m. EDT To access the call and webcast, please click h e re .
-
Vaccinex announced topline data from the early manifest treatment arm of its Phase II SIGNAL trial of pepinemab in patients with early manifest and prodromal Huntington’s disease.
-
Vaccinex, a company developing a novel approach to treat both cancer and neurodegenerative disease through the inhibition of SEMA4D, will pair its lead asset with Merck’s vaunted checkpoint inhibitor Keytruda.
-
Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
9/17/2020
Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a novel approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that it has entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada), through a subsidiary, to evaluate the combination of Vaccinex’s investigational SEMA4D inhibitor,
-
BioSpace Movers & Shakers, Aug. 28
8/28/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Vaccinex Announces Appointment of Robert Scala as Chief Commercial Officer
8/27/2020
Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s disease (HD) and cancer, announced the appointment of Robert Scala as Chief Commercial Officer.
-
Vaccinex Reports Second Quarter 2020 Financial Results and Provides Corporate Update
8/14/2020
On track to report potentially pivotal Phase 2 Huntington’s disease topline data by early October Phase 1/2 trial of pepinemab in Alzheimer’s disease to begin enrolling patients in September Raised net proceeds of $19.8 million since June 30 ROCHESTER, N.Y., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s disease and cancer, today announced financial results for
-
Clinical Catch-Up: July 6-10
7/13/2020
Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates. -
Vaccinex Provides Update of Potentially Pivotal SIGNAL Clinical Trial in Huntington’s DiseaseTopline data anticipated in October 2020 as previously guided
7/7/2020
Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s disease (HD) and cancer, today announced that, notwithstanding the challenges posed by the ongoing COVID-19 pandemic, it remains on track to complete the potentially pivotal SIGNAL trial in HD within the anticipated time frame. Primary efficacy data has been collected from all subjects who completed the stud
-
Vaccinex, Inc. to Present at the Virtual Investor Fireside Chat Series
6/9/2020
Live video moderated discussion with President and CEO, Maurice Zauderer, Ph.D., on Tuesday, June 16, at 10:00 AM ET, immediately followed by an interactive Q&A session
-
Vaccinex Reports First Quarter 2020 Financial Results and Provides Corporate Update
5/14/2020
Approaching key topline data in non-small cell lung cancer and Huntington’s disease Advancing plans to expand pepinemab development to include Alzheimer’s disease ROCHESTER, N.Y., May 14, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced financial results for the first quarter ended March 31, 2020 and provided a corporate update. First Qua
-
Vaccinex to Present Updated Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting
5/13/2020
Vaccinex, Inc. announced a poster presentation highlighting interim results from CLASSICAL-Lung, the Company’s Phase 1b/2 study of pepinemab in combination with the anti-PD-L1 checkpoint inhibitor BAVENCIO® in non-small cell lung cancer, at the American Society of Clinical Oncology 2020 Annual Meeting, being held virtually May 29-31, 2020.
-
Updated Interim Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer Presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting
4/27/2020
Updated data continue to demonstrate a durable clinical benefit in both immunotherapy-naïve patients as well as those previously treated with an immunotherapy regimen
-
Vaccinex Delivers Virtual Presentation at the Advances in Alzheimer’s and Parkinson’s Therapies AAT-AD/PD™ Focus Meeting 2020
4/7/2020
Presentation highlighted the potential of the company’s lead candidate, the anti-SEMA4D antibody pepinemab, to regulate glial cell activation and neurodegeneration in Alzheimer’s and Huntington’s disease